Who are R21Matrix M's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): RSV Vaccine, NVX-CoV2705 Vaccine, R21/Matrix-M™, NVX-CoV2515, Cervavac as two dose regimen, EuCorVac-19.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/r21matrix-m.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

R21Matrix M — Competitive Intelligence Brief

R21Matrix M (R21Matrix M) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant protein subunit vaccine. Area: Infectious Disease / Immunology.

phase 3 Recombinant protein subunit vaccine Plasmodium falciparum circumsporozoite protein (CSP) Infectious Disease / Immunology Biologic Live · refreshed every 30 min

Target snapshot

R21Matrix M (R21Matrix M) — London School of Hygiene and Tropical Medicine. R21/Matrix M is a recombinant protein subunit malaria vaccine that elicits immune responses against the Plasmodium falciparum parasite.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
R21Matrix M TARGET	R21Matrix M	London School of Hygiene and Tropical Medicine	phase 3	Recombinant protein subunit vaccine	Plasmodium falciparum circumsporozoite protein (CSP)
RSV Vaccine	RSV Vaccine	Pfizer	marketed	Recombinant protein subunit vaccine	Respiratory syncytial virus (RSV) fusion (F) glycoprotein
NVX-CoV2705 Vaccine	NVX-CoV2705 Vaccine	Novavax	phase 3	Recombinant protein subunit vaccine	SARS-CoV-2 spike protein
R21/Matrix-M™	R21/Matrix-M™	University of Oxford	phase 3	Recombinant protein subunit vaccine	Plasmodium falciparum circumsporozoite protein (CSP)
NVX-CoV2515	NVX-CoV2515	Novavax	phase 3	Recombinant protein subunit vaccine	SARS-CoV-2 spike protein
Cervavac as two dose regimen	Cervavac as two dose regimen	Serum Institute of India Pvt. Ltd.	phase 3	Recombinant protein subunit vaccine	HPV L1 capsid protein (types 16 and 18)
EuCorVac-19	EuCorVac-19	EuBiologics Co.,Ltd	phase 3	Recombinant protein subunit vaccine	SARS-CoV-2 spike protein (S protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant protein subunit vaccine class)

Novavax · 2 drugs in this class
London School of Hygiene and Tropical Medicine · 1 drug in this class
Medigen Vaccine Biologics Corp. · 1 drug in this class
EuBiologics Co.,Ltd · 1 drug in this class
Pfizer · 1 drug in this class
Serum Institute of India Pvt. Ltd. · 1 drug in this class
University of Oxford · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). R21Matrix M — Competitive Intelligence Brief. https://druglandscape.com/ci/r21matrix-m. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab